Drug Trial Radar · NCT01186770
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
Last checked: Nov 19, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
804
Actual
Start
Sep 1, 2010
Primary completion
Sep 8, 2011
Study completion Sep 8, 2011
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Progenics Pharmaceuticals, Inc.
- First posted
- Aug 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral MNTX for the treatment of opioid induced constipation in participants with chronic, non-malignant pain.
Conditions
- Opioid-Induced Constipation
Interventions
MethylnaltrexoneDrug
Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
PlaceboDrug
Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average Percentage of Dosing Days That Resulted in Rescue-Free Bowel Movements (RFBMs) Within 4 Hours of Dosing During Weeks 1 to 4Time frame: Weeks 1 to 4
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
PRA International
Raleigh, North Carolina
PRA, Intl.
Raleigh, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.